The results of phase two clinical trial CITYSCAPE (NCT03563716) indicated that in patients with non-small cell lung cancer with high PD-L1 expression, the combination of tirogolumab and Tecentriq (atezolizumab; mAbs anti-PD-L1) vs. atezolizumab plus placebo, clinically improved the progression-free survival and the objective response rate (ORR; respectively, PFS median 5.4 vs. 3.6 months; ORR median 37.3% vs. 20.6%). Here, CD274 is linked to non-small cell lung carcinoma.